Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by leishmania subgenus viannia species

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 144-152

  Obonaga, Ricardo ^a   Fernández, Olga Lucía ^a   Valderrama, Liliana ^a   Rubiano, Luisa Consuelo ^a   Castro, Maria Del Mar ^a   Barrera, Maria Claudia ^a   Gomez, Maria Adelaida ^a   Saravia, Nancy Gore ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A2; ABC TRANSPORTER A3; ABC TRANSPORTER G4; ABC TRANSPORTER G6; CARRIER PROTEIN; LBMT PROTEIN; MILTEFOSINE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; UNCLASSIFIED DRUG;

ADULT; AMASTIGOTE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LEISHMANIA BRAZILIENSIS; LEISHMANIA PANAMENSIS; MALE; MIDDLE AGED; MUCOSAL DISEASE; PARASITE ISOLATION; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION; SCHOOL CHILD; SKIN DEFECT; SKIN LEISHMANIASIS;

ADOLESCENT; ADULT; ATP-BINDING CASSETTE TRANSPORTERS; CHILD; DRUG RESISTANCE; FEMALE; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHOSPHORYLCHOLINE; PROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84891509972     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01023-13     Document Type: Article

References (29)

1. Berman J. 2005. Miltefosine to treat leishmaniasis. Expert Opin. Pharmacother. 6:1381-1388. http://dx.doi.org/10.1517/14656566.6.8.1381.
2. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H. 2004. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. 38: 1266-1272. http://dx.doi.org/10.1086/383321.
3. Velez I, Lopez L, Sanchez X, Mestra L, Rojas C, Rodriguez E. 2010. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 83:351-356. http://dx.doi.org/10.4269/ajtmh.2010.10-0060.
4. Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodriguez-Barraquer I, Garcerant D, Prager M, Osorio L, Rojas MX, Perez M, Nicholls RS, Gore Saravia N. 2012. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J. Infect. Dis. 205:684-692. http://dx.doi.org/10.1093/infdis/jir816.
5. Bryceson A. 2001. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health 6:928-934. http://dx.doi.org/10.1046/j.1365-3156.2001.00795.x.
6. Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ. 2008. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob. Agents Chemother. 52: 2855-2860. http://dx.doi.org/10.1128/AAC.00014-08.
7. Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, Miranda C, Llanos-Cuentas A, Chappuis F. 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73:272-275. http://www.ajtmh.org/content/73/2/272.long
8. Sanchez-Canete MP, Carvalho L, Perez-Victoria FJ, Gamarro F, Castanys S. 2009. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob. Agents Chemother. 53:1305-1313. http://dx.doi.org/10.1128/AAC.01694-08.
9. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. 2003. Functional cloning of the miltefosine transporter. A novel P-type phospholipids translocase from Leishmania involved in drug resistance. J. Biol. Chem. 278:49965-49971. http://dx.doi.org/10.1074/jbc.M308352200.
10. Doern GV, Brecher SM. 2011. The clinical predictive value (or lack thereof) of the results of in vitro antimicrobial susceptibility tests. J. Clin. Microbiol. 49:S11. http://dx.doi.org/10.1128/JCM.00580-11.
11. Nguyen MH, Yu VL, Morris AJ, McDermott L, Wagener MW, Harrell L, Snydman DR. 2000. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin. Infect. Dis. 30:870-876. http://dx.doi.org/10.1086/313805.
12. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. 2003. Comparison of mortality associated with methicillin-resistant and methicillin- susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36:53-59. http://dx.doi.org/10.1086/345476.
13. Saravia NG, Holguin AF, McMahon-Pratt D, D'Alessandro A. 1985. Mucocutaneous leishmaniasis in Colombia: Leishmania braziliensis subspecies diversity. Am. J. Trop. Med. Hyg. 34:714-720.
14. Roy G, Dumas C, Sereno D, Wu Y, Singh AK, Tremblay MJ, Ouellette M, Olivier M, Papadopoulou B. 2000. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol. Biochem. Parasitol. 110:195-206. http://dx.doi.org/10.1016/S0166-6851(00)00270-X.
15. Fernandez O, Diaz-Toro Y, Valderrama L, Ovalle C, Valderrama M, Castillo H, Perez M, Saravia NG. 2012. Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp. J. Clin. Microbiol. 50:2207-2211. http://dx.doi.org/10.1128/JCM.00216-12.
16. Bodley AL, McGarry MW, Shapiro TA. 1995. Drug cytotoxicity assay for African trypanosomes and Leishmania species. J. Infect. Dis. 172:1157-1159. http://dx.doi.org/10.1093/infdis/172.4.1157.
17. Castanys-Muñoz E, Alder-Baerens N, Pomorski T, Gamarro F, Castanys S. 2007. A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids. Mol. Microbiol. 64:1141-1153. http://dx.doi.org/10.1111/j. 1365-2958.2007.05653.x.
18. Castanys-Muñoz E, Pérez-Victoria JM, Gamarro F, Castanys S. 2008. Characterization of an ABCG-like transporter from the protozoan para-site Leishmania with a role in drug resistance and transbilayer lipid movement. Antimicrob. Agents Chemother. 52:3573-3579. http://dx.doi.org/10.1128/AAC.00587- 08.
19. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P. 2012. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl. Trop. Dis. 6:e1657. http://dx.doi.org/10.1371/journal.pntd.0001657.
20. Rakotomalala R. 2005. TANAGRA: a free software for research and academic purposes, p. 697-702. In Proceedings of European Grid Conference 2005, vol 2. RNTI-E-3. (In French.)
21. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J. 2012. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin. Infect. Dis. 55:543-550. http://dx.doi.org/10.1093/cid/cis474.
22. Cojean S, Houze S, Haouchine D, Huteau F, Lariven S, Hubert V, Michard F, Bories C, Pratlong F, Le Bras J, Loiseau PM, Matheron S. 2012. Leishmania resistance to miltefosine associated with genetic marker. Emerg. Infect. Dis. 18:704 -706. http://dx.doi.org/10.3201/eid1804.110841.
23. Dorlo TP, Huitema AD, Beijnen JH, de Vries PJ. 2012. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob. Agents Chemother. 56:3864-3872. http://dx.doi.org/10.1128/AAC.00292-12.
24. Vargas-Gonzalez A, Canto-Lara SB, Damian-Centeno AG, Andrade- Narvaez FJ. 1999. Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico. Am. J. Trop. Med. Hyg. 61:960-963.
25. Amato VS, Tuon FF, Imamura R, Abegao de Camargo R, Duarte MI, Neto VA. 2009. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J. Eur. Acad. Dermatol. Venereol. 23:1026-1034. http://dx.doi.org/10. 1111/j.1468-3083.2009.03238.x.
26. Dey T, Afrin F, Anam K, Ali N. 2002. Infectivity and virulence of Leishmania donovani promastigotes: a role for media, source, and strain of parasite. J. Eukaryot. Microbiol. 49:270-274. http://dx.doi.org/10.1111/j.1550- 7408.2002.tb00369.x.
27. Vermeersch M, da Luz RI, Tote K, Timmermans JP, Cos P, Maes L. 2009. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob. Agents Chemother. 53:3855-3859. http://dx.doi.org/10. 1128/AAC.00548-09.
28. Azzouz S, Maache M, Garcia RG, Osuna A. 2005. Leishmanicidal activity of edelfosine, miltefosine and ilmofosine. Basic Clin. Pharmacol. Toxicol. 96:60-65. http://dx.doi.org/10.1111/j.1742-7843.2005.pto960109.x.
29. Matsumura Y, Sakai H, Sasaki M, Ban N, Inagaki N. 2007. ABCA3- mediated choline-phospholipids uptake into intracellular vesicles in A549 cells. FEBS Lett. 581:3139-3144. http://dx.doi.org/10.1016/j.febslet.2007.05.078.